Key Events This Week
27 Apr: Stock opens strong at Rs.273.70 (+4.23%)
28 Apr: New 52-week high and all-time high reached (Rs.280.2 / Rs.278.2)
29 Apr: Minor consolidation with slight declines
30 Apr: Strong rebound closes week at Rs.276.25 (+3.17%)
May 11
BSE+NSE Vol: 1.93 lacs
The next results date for Bliss GVS Pharma Ltd is scheduled for 12 May 2026....
Read full news article
27 Apr: Stock opens strong at Rs.273.70 (+4.23%)
28 Apr: New 52-week high and all-time high reached (Rs.280.2 / Rs.278.2)
29 Apr: Minor consolidation with slight declines
30 Apr: Strong rebound closes week at Rs.276.25 (+3.17%)

Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
With a remarkable 122.33% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 280.2 on 28 Apr 2026, outpacing the Sensex which declined by 3.62% during the same period. This milestone caps a sustained rally fuelled by strong technical momentum and a series of bullish signals across multiple timeframes.
Read full news article
20 Apr: Stock opens at Rs.253.40, down 1.92% amid flat Sensex
22 Apr: New 52-week high at Rs.272.95 and all-time high at Rs.271.65
23 Apr: Further 52-week and all-time highs at Rs.277.7 and Rs.277.45
24 Apr: Week closes at Rs.262.60, down 2.36% on the day

With a remarkable 120.83% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 277.7 on 23 Apr 2026, showcasing a sustained momentum that outpaces the broader Sensex, which declined by 2.58% over the same period.
Read full news article
From a 52-week low of Rs 105.05 to a new peak of Rs 272.95, Bliss GVS Pharma Ltd has more than doubled in value over the past year, delivering a remarkable 119.3% return. This surge comes amid a backdrop of mixed market conditions, with the Sensex down 0.73% today but up nearly 7% over the last three weeks, highlighting the stock’s standout momentum in the Pharmaceuticals & Biotechnology sector.
Read full news articleBliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 inter alia to consider and approve 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2026 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon; 2. The Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31 2026 and 3.Recommend the Final Dividend if any for the financial year ended March 31 2026.
Please find enclosed herewith the Newspaper publication regarding the dispatch of the Notice of Postal Ballot and E-voting Information.
Please find enclosed herewith the Postal Ballot Notice regarding the appointment of an Independent Director of the Company.
12 May 2026
Bliss GVS Pharma Ltd has declared 50% dividend, ex-date: 18 Feb 26
Bliss GVS Pharma Ltd has announced 1:10 stock split, ex-date: 11 Mar 08
Bliss GVS Pharma Ltd has announced 3:5 bonus issue, ex-date: 26 Sep 08
No Rights history available